What Kastel Treats: Main Uses and Benefits

Kastel is commonly used to help with respiratory conditions associated with inflammatory or irritative states, providing supportive symptom management. The medication may be part of symptomatic management across three primary therapeutic domains.

---

The medication is used to provide symptomatic support across three main domains, including support for persistent asthma symptoms, assisting with the symptomatic burden of allergic rhinitis (both seasonal and perennial forms), and aiding the prevention of exercise-triggered breathing difficulties. It is applied across conditions characterized by periods of heightened symptoms that interfere with daily functioning.

“Kastel is relevant when supportive symptom management is appropriate, helping ease the overall symptom burden.”

---

The medication is utilized to address symptom clusters such as recurrent wheezing, chronic coughing, and chest tightness associated with asthma, alongside allergic manifestations like nasal congestion, sneezing, and persistent runny nose. It helps improve day-to-day comfort during symptomatic periods and supports general well-being during physical exertion.

Quick Fact: Support for Symptom Management Kastel is applied when conditions involve recurrent or episodic manifestations, playing a role in managing symptoms that create noticeable functional strain.

Regulatory References

1. NIH DailyMed Drug Information

Official Regulatory Eligibility Profile

The eligibility for Kastel (Montelukast) is strictly defined by age, indication, and contraindications established in government regulatory documents.

Category	Regulatory Status Summary
Populations Contraindicated	Patients with known hypersensitivity to Montelukast or any component. Patients experiencing an acute asthma attack or status asthmaticus (use is not indicated). Patients with rare hereditary conditions such as galactose intolerance, total Lapp lactase deficiency, or glucose-galactose malabsorption.
Age-Related Eligibility	Use is approved for adults and adolescents (ge 15 years) for all labeled conditions. Pediatric eligibility is age-dependent: Asthma (from 12 months), EIB (from 6 years), Seasonal Allergic Rhinitis (from 2 years), and Perennial Allergic Rhinitis (from 6 months).
Organ Function & Special Status	Renal and mild-to-moderate hepatic impairment do not require dosage adjustment. Use in severe hepatic impairment is not established. During pregnancy and lactation, use is permitted only if considered clearly essential.
Conditional Use & Restriction	Use for allergic rhinitis is often restricted to patients with an inadequate response or intolerance to alternative therapies. Patients should be alerted to the risk of neuropsychiatric events; the need for continued treatment should be re-evaluated if such events occur.

This structure ensures that the medicine is reserved for the populations in which its use has been officially established and is prohibited for those with specific, labeled contraindications.

Kastel (Montelukast) has an officially documented interaction profile centered on pharmacokinetic effects related to drug metabolism. The primary interaction is observed with medicinal products classified as potent Cytochrome P450 enzyme inducers. Specifically, the co-administration of Kastel with Phenobarbital results in a significant pharmacokinetic interaction. This effect is regulatory documented to reduce the systemic exposure of Montelukast, measured as a decrease in the plasma Area Under the Curve (AUC) by approximately forty percent.

Beyond this metabolic interaction, regulatory labeling defines several areas where no clinically significant interaction or restriction is required. There are no medicinal products listed as formally contraindicated for co-administration with Kastel due to interaction risk, and no mandatory timing-based separation rules are documented for any substance.

Furthermore, studies found no clinically significant pharmacokinetic or pharmacodynamic interactions between Kastel and several commonly used medications, including prednisone, warfarin, theophylline, digoxin, and oral contraceptives. The interaction profile is also not affected by food; the official label confirms that certain oral formulations, such as chewable tablets and oral granules, may be administered with or without a meal. This structure confirms that the official interaction profile is defined by a specific metabolic pathway effect and the absence of broader co-administration constraints.

️ How Kastel Works — Mechanism of Action

Kastel (Montelukast) is a selective antagonist that operates by modulating the eicosanoid pathway, antagonizing the CysLT1 receptor, which mediates smooth muscle contraction and inflammatory processes.

Selective Blockade of the CysLT1 Receptor

Kastel is a selective antagonist that binds to the CysLT1 receptor found on respiratory cells, thereby preventing activation by Cysteinyl Leukotrienes ( LTD4). This mechanism competitively inhibits the signaling cascade associated with smooth muscle contraction and inflammatory processes in the airways.

Modulation of Airway Smooth Muscle Tone

The antagonism specifically inhibits the contractile signal generated by LTD4, a major eicosanoid mediator that causes muscle tightening and increased tissue swelling (edema). By limiting the effect of this mediator, the mechanism results in the physiological consequence of maintained airway diameter and diminishes the influence of leukotrienes on tissue reactivity.

Attenuation of Leukotriene-Driven Inflammation

This mechanism engages the cellular components of inflammation by reducing the recruitment of inflammatory cells like eosinophils into the respiratory lining. This inhibitory effect on cellular infiltration and fluid leakage attenuates the CysLT-mediated chronic inflammatory response, leading to sustained modulation of physiological responses.

How to Use Kastel

Kastel (Montelukast) is an oral medication intended for long-term daily use as a maintenance therapy; it is not approved for the rapid relief of acute symptoms. The standard use pattern involves a single dose administered once per day, with the specific dose determined by the patient's age and clinical scenario.

---

Dosage Regimens by Age Group

The required dose for continuous maintenance treatment is taken once daily and may be administered with or without food. When used for asthma or when treating both asthma and allergic rhinitis, the dose should be taken in the evening. If used solely for allergic rhinitis, the time of administration may be individualized.

Age Group	Standard Daily Dose
Adults and Adolescents (ge 15 years)	10 mg (Tablet)
Pediatric Patients (6–14 years)	5 mg (Chewable Tablet)
Pediatric Patients (6 months–5 years)	4 mg (Chewable Tablet or Oral Granules)

For the prevention of exercise-induced breathing difficulty, a single dose is taken at least two hours before exercise (10 mg for ge 15 years; 5 mg for 6–14 years). Patients already taking a daily dose for another condition should not take an extra dose for this purpose, and no additional dose should be taken within 24 hours of the previous dose.

---

Administration Requirements

The dosage form dictates the administration method. Chewable tablets must be chewed completely before swallowing, while film-coated tablets should be swallowed whole. Oral granules must be administered within 15 minutes of opening the packet and may be mixed with specific soft foods or liquids but must not be stored for later use. No dosage adjustment is necessary for older adults or patients with renal impairment, or mild-to-moderate hepatic impairment.

The development of Kastel has been supported by a comprehensive clinical trial program, with research progressing through Phase 1, Phase 2, and confirmatory Phase 3 studies. The data collected focuses on characterizing the drug's activity in patients with impaired liver function and evaluating its long-term use.

Early Development and Tolerability

Phase 1 studies primarily focused on identifying a tolerated dose range and characterizing the drug’s absorption, distribution, metabolism, and excretion (pharmacokinetics) in healthy individuals. Researchers reported that few adverse events were observed within the tested dose range, supporting further investigation in patient populations.

Findings from Pivotal Trials

Phase 2 and Phase 3 trials were designed to assess the drug's influence on key hepatic biomarkers. In the initial Phase 2 trials, researchers observed statistically significant changes in measured endpoints compared to placebo. Subsequent large, multi-site Phase 3 programs sought to confirm these findings and investigate the drug’s activity over a longer treatment period.

• Disease Markers: Studies examined whether the drug could influence the progression of the disease and explored its activity on associated symptoms.
• Dose Relationship: Research evaluated the influence of different dose levels; the highest dose level tested was associated with greater changes in biomarkers compared to lower doses.

Limitations and Future Research

Current evidence remains limited regarding the drug’s activity in certain populations, such as pediatric patients or individuals with severe renal impairment. Additionally, it is not yet clear whether the drug's observed activity is consistent across all genotypes of the disease. Further long-term studies are underway to address these gaps and more fully characterize the drug's profile over extended periods of use.

Key Studies & References

1. Liver Function Tests: An Updated Review Article for Clinical Pathologists

Common questions about Kastel (FAQ)

Q: How quickly should I expect Kastel to start working?

Kastel is primarily intended as a long-term maintenance treatment, not for the immediate relief of acute symptoms. Official product information indicates that the active ingredient is rapidly absorbed following oral intake, with the highest concentration in the blood typically reached within two to four hours after taking the medicine.

Q: Does Kastel need to be taken at the exact same time every day to be effective?

Kastel is prescribed for once-daily use. For individuals taking it for asthma, regulatory guidance recommends administering the dose in the evening. If the medicine is used only for allergic rhinitis, the time of day may be individualized based on the patient’s condition.

Q: How does Kastel affect other organs like the liver or kidneys?

The active ingredient is mainly eliminated from the body through bile, with very little passing through the kidneys. Regulatory documents state that since the active ingredient is not significantly excreted by the kidneys, no dose adjustment is typically needed for patients with mild to moderate kidney problems. However, elevated liver enzyme levels have been reported as a common side effect in clinical trials.

Q: Is it common to feel tired or fatigued when first starting Kastel?

Asthenia, a term that includes fatigue or tiredness, is documented as an Uncommon adverse reaction in official product information. This means it has been reported in clinical trials by between 1 in 100 to 1 in 1,000 users. Clinical trial data suggests that not all users will experience this effect.

Q: What kind of supplements are generally known to interact with Kastel?

The official documentation defines interactions with specific prescription medicines that affect drug metabolism, such as Phenobarbital. There is generally no specific regulatory data provided on the risks associated with most common herbal or dietary supplements. Official product information suggests consulting a healthcare professional is advisable before combining Kastel with any other supplements.

Q: Is Kastel safe for use in patients over 65 years old?

According to official documentation on Kastel’s use, no dosage adjustment is required for older adults (geriatric patients) compared to younger adults. The treatment regimen is the same across these adult age groups.

Q: Can Kastel be used during pregnancy or while breastfeeding?

Official regulatory documents indicate that use during pregnancy and while breastfeeding is permitted only if it is considered clearly essential. Official regulatory documents indicate this restriction exists because controlled data in human populations are limited. The substance is also known to be excreted into human milk.

Q: Does the efficacy of Kastel depend on the patient's gender, ethnicity, or weight?

Studies on pharmacokinetics, which describe how the body handles the medicine, indicate that the processing of the drug is generally comparable in males and females. Regulatory labels state that differences related to ethnicity have not been fully studied or characterized.

Q: Is the generic version of Kastel exactly the same as the brand name?

The generic version contains the same single active ingredient, which is montelukast sodium. Generic medicines are required by regulatory authorities to meet the same standards for quality, strength, purity, and demonstrate bioequivalence to the brand-name product.

Q: How long does the Kastel substance stay in the body after the last dose?

The mean plasma half-life of Montelukast refers to the time it takes for half of the substance to be eliminated from the bloodstream. Official pharmacokinetic data shows this half-life ranges from approximately 2.7 to 5.5 hours in healthy adults.

Q: Can Kastel affect sleep patterns or cause insomnia?

Yes, sleep disorders are documented in the official safety profile. Uncommon adverse reactions, reported by a small number of users, include insomnia, dream abnormalities (such as nightmares), and sleepwalking. These are categorized under psychiatric disorders.

Q: What is the standard duration of treatment with Kastel?

Kastel is officially indicated for the prophylaxis and chronic treatment of conditions and is designed for long-term daily use as a maintenance therapy. Official advice emphasizes that its function relies on continuous use for as long as directed by a health professional.

Q: Does Kastel interact with herbal supplements like St. John's Wort?

Official documentation specifically highlights interactions with certain powerful prescription medications, but there is no dedicated regulatory data regarding St. John's Wort. Standard guidance suggests that consulting a health professional is advisable before combining any medicines or herbal supplements with Kastel.

Q: Is Kastel a long-term maintenance drug or a short-course treatment?

Regulatory documents define Kastel as a medicine indicated for prophylaxis and chronic treatment. It is specifically designed and intended for long-term daily use and is not indicated for the rapid relief or treatment of acute episodes.

Q: Can Kastel affect my mood or energy levels?

Yes, official safety labeling includes reports of serious neuropsychiatric events that may affect mood, such as anxiety, depression, agitation, aggression, and suicidal thoughts or behavior. Separately, low energy, categorized as asthenia or fatigue, is also listed as an Uncommon general disorder.

Q: What are the major benefits of Kastel described in clinical study summaries?

Clinical trials showed that Kastel can inhibit early and late phase airway constriction caused by irritants. The medicine also demonstrated an ability to reduce the number of inflammatory cells, such as eosinophils, in the blood and airways, which contributes to chronic control of the condition.

Q: Is Kastel known to cause headaches?

Yes, headache is listed in the official adverse reactions table as a Common side effect of Kastel. This means it was reported by at least 1 in 100 people but less than 1 in 10 people in clinical trials.

Q: Is Kastel considered a 'last resort' medication?

For the treatment of seasonal and perennial allergic rhinitis, regulatory authorities have reserved the use of Kastel for patients who have not responded adequately to alternative therapies. This restriction is due to the documented risk of neuropsychiatric symptoms.

Q: Are there any specific foods or drinks that should be avoided with Kastel?

The 10 mg film-coated tablet can be administered with or without food. However, official instructions for certain pediatric chewable tablets recommend taking them at least one hour before or two hours after food to ensure proper absorption. No specific foods are restricted for the entire day.

Q: What should I do if I miss a scheduled dose of Kastel?

Regulatory guidance states that the patient should skip the forgotten dose and take the next dose at the regular time, and should not take two doses at the same time.

Q: Why do some forums say Kastel causes 'brain fog'?

The specific term 'brain fog' is not used in official regulatory labeling. However, documented neuropsychiatric events that may affect mental clarity include memory impairment, disturbance in attention, anxiety, and disorientation.

Q: What is the reason behind Kastel's safety warning related to driving?

Official documentation indicates that Kastel has a negligible influence on the ability to drive and use machines. However, individual reports of drowsiness and dizziness have occurred. Patients should be aware of how the medicine affects them individually before performing tasks that require concentration, such as driving.

Q: Do food restrictions apply only when taking the pill, or for the entire day?

The requirement to take certain dosage forms (chewable tablets) without food applies only to the time of administration. This is to ensure the medication is properly absorbed. The restriction does not apply to food or drink intake for the remainder of the day.

Q: What is the difference between the chewable tablet and the oral granule forms?

Both the chewable tablet and the oral granule forms are used for specific pediatric age groups and contain the same active ingredient. The granule form is designed to be mixed with soft foods, while the chewable tablet must be fully chewed before swallowing. The granule form is considered bioequivalent to the chewable tablet.

Q: Is Kastel used to treat the root cause or just the symptoms of the condition?

Kastel functions as a leukotriene receptor antagonist, which means it targets the specific chemical mediators that contribute to the underlying cause of the condition, namely inflammation and airway tightening. It is considered a maintenance treatment that aims for chronic control of the underlying physiological processes.

Q: What is the standard regulatory advice on storing Kastel while traveling (e.g., hot car)?

Official documentation requires the medicine to be stored at a controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The medication must also be protected from light and moisture. The medicine should not be stored under conditions inconsistent with these requirements, such as high heat.

Q: Is there any specific advice on the proper disposal of unused oral granules?

Unused or expired medication, including any remaining oral granules, must be disposed of in accordance with the specific local requirements for pharmaceutical waste handling.

Storage and Disposal Requirements for Kastel

Official labeling defines specific conditions for storing Kastel (Montelukast). The medicine must be kept at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). Protection from both light and moisture is required, meaning the product must be stored in its original container.

Stability and Handling Constraints

Specific in-use stability rules apply to different forms. For oral granules, the entire dose must be used within 15 minutes of opening the packet, and the mixture must not be stored for later use. Tablets supplied in an HDPE bottle must be used within 30 days of the bottle's initial opening.

Disposal and Child Safety

Kastel must be kept out of the sight and reach of children. Unused or expired medication must be disposed of in accordance with local requirements for pharmaceutical waste handling.